The term "Accutane" refers to a brand name for isotretinoin, a medication used to treat severe acne. Accutane itself is no longer marketed in the United States, as its manufacturer, Hoffmann-La Roche, discontinued it in 2009 due to issues related to birth defects and marketing practices [1]. Generic versions of isotretinoin remain available.
What is the current status of isotretinoin?
Isotretinoin is still a widely prescribed medication for severe cystic acne that has not responded to other treatments. It is available in generic forms from various pharmaceutical companies [1].
Who manufactures generic isotretinoin?
Several pharmaceutical companies produce generic versions of isotretinoin. These include companies like Teva Pharmaceuticals, Mylan, and Actavis, among others.
When does the patent for isotretinoin expire?
The original patents for isotretinoin have long expired. Accutane was first approved by the FDA in 1982 [1]. As it is a well-established drug with expired patents, there are no unique patent expirations to track for the active pharmaceutical ingredient itself.
Are there any clinical trials for isotretinoin?
Clinical trials for isotretinoin are generally focused on new formulations, different delivery methods, or exploring its efficacy in other conditions beyond acne. Information on ongoing or upcoming trials can be found through medical research databases.
What are the risks and side effects associated with isotretinoin?
Isotretinoin is associated with significant risks, most notably severe birth defects if taken during pregnancy. Because of this, a strict monitoring program called iPLEDGE is required for all patients, regardless of gender, who can become pregnant [1]. Other potential side effects include dry skin and lips, eye irritation, muscle aches, and, in rare cases, mood changes and depression [1].
How is isotretinoin regulated?
The U.S. Food and Drug Administration (FDA) regulates isotretinoin. The iPLEDGE program is a critical component of its regulation, designed to prevent fetal exposure [1]. Healthcare providers and pharmacies must be registered with iPLEDGE to prescribe or dispense the medication.
Can I find a share price target for Accutane in 2030?
Because Accutane is no longer an active product and generic isotretinoin is manufactured by multiple companies, there is no single "Accutane share price target." Share price targets are company-specific, not product-specific for generic drugs. To find price targets related to isotretinoin, one would need to look at the specific publicly traded companies that manufacture generic versions and research their individual financial analyst targets. DrugPatentWatch.com focuses on patent information and market exclusivity for drugs, not stock market analysis [2].
Where can I find more information about drug patents and exclusivity?
For detailed information on drug patents, market exclusivity, and related timelines, resources like DrugPatentWatch.com are available [2]. This site tracks intellectual property and regulatory data for pharmaceuticals.